Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 15;130(12):2169-2179.
doi: 10.1002/cncr.35234. Epub 2024 Feb 6.

Post-diagnostic multivitamin supplement use and colorectal cancer survival: A prospective cohort study

Ming-Ming He  1   2 , Kai Wang  2 , Chun-Han Lo  2   3   4 , Yiwen Zhang  2 , Georgios Polychronidis  2   5   6 , Markus D Knudsen  2   7   8 , Rong Zhong  2 , Yuan Ma  2 , Kana Wu  9 , Andrew T Chan  3   4   10   11 , Edward L Giovannucci  2   9   10 , Shuji Ogino  2   11   12 , Kimmie Ng  13 , Jeffrey A Meyerhardt  13 , Mingyang Song  2   3   4   9
Affiliations

Post-diagnostic multivitamin supplement use and colorectal cancer survival: A prospective cohort study

Ming-Ming He et al. Cancer. .

Abstract

Background: Use of multivitamin supplements has been associated with lower incidence of colorectal cancer (CRC). However, its influence on CRC survival remains unknown.

Methods: Among 2424 patients with stage I-III CRC who provided detailed information about multivitamin supplements in the Nurses' Health Study and Health Professionals Follow-up Study, the authors calculated multivariable hazard ratios (HRs) of multivitamin supplements for all-cause and CRC-specific mortality according to post-diagnostic use and dose of multivitamin supplements.

Results: During a median follow-up of 11 years, the authors documented 1512 deaths, among which 343 were of CRC. Compared to non-users, post-diagnostic users of multivitamin supplements at a dose of 3-5 tablets/week had lower CRC-specific mortality (HR, 0.55; 95% confidence interval [CI], 0.36-0.83, p = .005), and post-diagnostic users at doses of 3-5 and 6-9 tablets/week had lower all-cause mortality (HR, 0.81; 95% CI, 0.67-0.99, p = .04; HR, 0.79; 95% CI, 0.70-0.88), p < .001). The dose-response analysis showed a curvilinear relationship for both CRC-specific (pnonlinearity < .001) and all-cause mortality (pnonlinearity = .004), with the maximum risk reduction observed at 3-5 tablets/week and no further reduction at higher doses. Compared to non-users in both pre- and post-diagnosis periods, new post-diagnostic users at dose of <10 tablets/week had a lower all-cause mortality (HR, 0.81; 95% CI, 0.71-0.94, p = .005), whereas new users at a dose of ≥10 tablets/week (HR, 1.58; 95% CI, 1.07-2.33) and discontinued users (HR, 1.35; 95% CI, 1.14-1.59) had a higher risk of mortality.

Conclusions: Use of multivitamin supplements at a moderate dose after a diagnosis of nonmetastatic CRC is associated with lower CRC-specific and overall mortality, whereas a high dose (≥10 tablets/week) use is associated with higher CRC-specific mortality.

Keywords: colorectal cancer; mortality; multivitamin; nonmetastasis; post‐diagnosis; survival.

PubMed Disclaimer

Conflict of interest statement

Disclosure

All the authors declare no conflict of interests.

Similar articles

See all similar articles

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68: 394–424. - PubMed
    1. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69: 363–385. - PubMed
    1. Velicer CM, Ulrich CM. Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol. 2008;26: 665–673. - PubMed
    1. Van Loon K, Wigler D, Niedzwiecki D, et al. Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. Clin Colorectal Cancer. 2013;12: 95–102. - PMC - PubMed
    1. Saeed Ali M, Mohamed Hussein R, Ahmed Kandeil M. The Pro-Oxidant, Apoptotic and Anti-Angiogenic Effects of Selenium Supplementation on Colorectal Tumors Induced by 1,2-Dimethylhydrazine in BALB/C Mice. Rep Biochem Mol Biol. 2019;8: 216–226. - PMC - PubMed

LinkOut - more resources